Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis

开发多功能药物和免疫调节剂递送纳米粒子,用于治疗患有动脉粥样硬化的癌症患者

基本信息

  • 批准号:
    10548149
  • 负责人:
  • 金额:
    $ 53.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-02-01 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

Project Summary Cancer and cardiovascular disease are leading causes of death in the United States. Given the high percentage of cancer patients with co-existing atherosclerosis, the development of cancer therapeutics that prevent progression of atherosclerosis have the potential to align cancer therapy goals with favorable cardiovascular outcomes. Hyaluronic acid (HA) has unique properties that are desirable for the development of biocompatible and biodegradable nanoparticle drug delivery systems for both cancer and atherosclerosis. We have developed a hyaluronic acid nanoparticle (HANP) conjugated with PD1 memetic peptides that target and block immune checkpoint protein PD-L1 and carry the cholesterol-lowering drug Avasimibe (PD1Y-HANP/Ava). Avasimibe is a multifunctional agent that decreases cholesterol accumulation, inhibits tumor cell growth, and enhances immune response by activating cytotoxic T cells. We found that systemic administrations of PD1Y-HANP/Ava led to targeted delivery into tumors and atherosclerotic plaques, inhibition of tumor growth and atherosclerosis progression, and significant improvement in mouse survival in a dual mouse cancer and atherosclerosis model. In this study, we hypothesize that systemic delivery of urokinase plasminogen activator receptor (uPAR), PD- L1 and CD44 co-targeted HANP carrying Avasimibe (ATF/PD1Y-HANP/Ava) leads to the efficient delivery of the HANP/Ava into tumors and atherosclerotic plaques, resulting in a significant anti-tumor growth effect by direct inhibition of tumor cell proliferation, activation of cytotoxic CD8+ T cells, and pro-immune modulatory effect of ATF/PD1Y-HANP/Ava in tumor microenvironment. We further hypothesize that delivery of targeted PD1Y- HANP/Ava into atherosclerotic plaques decreases cholesterol-rich macrophages and infiltrating immune cells, and thereby prevents atherosclerosis progression. To develop and validate the proposed immunotherapy, we will first develop ATF/PD1Y-HANP/Ava and examine the efficiency of targeted delivery in metastatic mouse colon cancer models (Aim 1). Therapeutic efficacy and immune responses following targeted PD1Y-HANP/Ava treatment, alone or in combination with a chemotherapy drug, irinotecan, will be evaluated in the mouse cancer models (Aim 1). We will then determine the effect of the targeted PD1Y-HANP/Ava on targeted delivery, immune responses and therapeutic efficacy in tumor and atherosclerotic plaques in a dual mouse colon cancer and atherosclerosis model (Aim 2). Immunological analysis of tumors and atherosclerotic plaques will allow us to determine therapy-related changes in immune cell types and functions, especially CD8+ T cell activity. We will then investigate the feasibility of translation in cancer patients by examining targeted delivery and direct cytotoxic effect of the targeted PD1Y-HANP/Ava in colon cancer patient derived xenograft models (Aim 3). Finally, pharmacokinetics, toxicity, biodistribution and systemic immune responses will be determined in mice (Aim 4). Results of this research should provide us with preclinical data for translational development of a phase 1 clinical trial using this novel targeted immunotherapy for metastatic colon cancer patients with comorbid atherosclerosis.
项目摘要 癌症和心血管疾病是美国的主要死亡原因。鉴于高比例的 同时存在动脉粥样硬化的癌症患者中, 动脉粥样硬化的进展有可能使癌症治疗目标与有利的心血管疾病相一致。 结果。透明质酸(HA)具有独特的性质,其对于生物相容性药物的开发是期望的。 以及用于癌症和动脉粥样硬化的可生物降解的纳米颗粒药物递送系统。我们已经开发 一种与PD 1蛋白肽缀合的透明质酸纳米颗粒(HANP),其靶向并阻断免疫 检查点蛋白PD-L1并携带降胆固醇药物Avasimibe(PD 1 Y-HANP/Ava)。Avasimibe是一种 一种减少胆固醇积累、抑制肿瘤细胞生长和增强免疫功能的多功能药剂, 通过激活细胞毒性T细胞的反应。我们发现,PD 1 Y-HANP/Ava的全身给药导致 靶向递送到肿瘤和动脉粥样硬化斑块中,抑制肿瘤生长和动脉粥样硬化 进展,以及在双重小鼠癌症和动脉粥样硬化模型中小鼠存活率的显著改善。 在这项研究中,我们假设全身递送尿激酶纤溶酶原激活物受体(uPAR),PD- 携带Avasimibe的L1和CD 44共靶向HANP(ATF/PD 1 Y-HANP/Ava)导致有效递送 HANP/Ava可直接进入肿瘤和动脉粥样硬化斑块,产生显著的抗肿瘤生长作用, 肿瘤细胞增殖的抑制、细胞毒性CD 8 + T细胞的活化和 肿瘤微环境中的ATF/PD 1 Y-HANP/Ava。我们进一步假设,靶向PD 1 Y的递送- HANP/Ava进入动脉粥样硬化斑块减少了富含胆固醇的巨噬细胞和浸润的免疫细胞, 从而防止动脉粥样硬化进展。为了开发和验证所提出的免疫疗法,我们 将首先开发ATF/PD 1 Y-HANP/Ava,并检查转移性小鼠结肠中靶向递送的效率 癌症模型(Aim 1)。靶向PD 1 Y-HANP/Ava后的疗效和免疫应答 将在小鼠癌症中评价单独或与化疗药物伊立替康组合的治疗 模型(目标1)。然后,我们将确定靶向PD 1 Y-HANP/Ava对靶向递送、免疫应答和免疫应答的影响。 在双重小鼠结肠癌中的肿瘤和动脉粥样硬化斑块中的反应和治疗功效, 动脉粥样硬化模型(目的2)。肿瘤和动脉粥样硬化斑块的免疫学分析将使我们能够 确定免疫细胞类型和功能的治疗相关变化,特别是CD 8 + T细胞活性。我们将 然后通过检查靶向递送和直接细胞毒性来研究在癌症患者中翻译的可行性, 靶向PD 1 Y-HANP/Ava在结肠癌患者来源的异种移植物模型中的作用(目的3)。最后, 将在小鼠中测定药代动力学、毒性、生物分布和全身免疫应答(目的4)。 这项研究的结果应该为我们提供临床前数据的翻译发展的1期临床 试验使用这种新的靶向免疫治疗转移性结肠癌患者合并动脉粥样硬化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lily Yang其他文献

Lily Yang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lily Yang', 18)}}的其他基金

Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis
开发多功能药物和免疫调节剂递送纳米粒子,用于治疗患有动脉粥样硬化的癌症患者
  • 批准号:
    10334547
  • 财政年份:
    2021
  • 资助金额:
    $ 53.22万
  • 项目类别:
Translational Development of a Targeted and Stroma-penetrating Nanoparticle Drug for Pancreatic Cancer Therapy
用于胰腺癌治疗的靶向基质穿透纳米颗粒药物的转化开发
  • 批准号:
    10705200
  • 财政年份:
    2019
  • 资助金额:
    $ 53.22万
  • 项目类别:
Translational Development of a Targeted and Stroma-breaking Nanoparticle Drug for Pancreatic Cancer Therapy
用于胰腺癌治疗的靶向和基质破坏纳米颗粒药物的转化开发
  • 批准号:
    9907528
  • 财政年份:
    2019
  • 资助金额:
    $ 53.22万
  • 项目类别:
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles
使用治疗诊断纳米颗粒靶向治疗三阴性乳腺癌
  • 批准号:
    8700565
  • 财政年份:
    2013
  • 资助金额:
    $ 53.22万
  • 项目类别:
Mechanisms of Herceptin resistance
赫赛汀耐药机制
  • 批准号:
    8934546
  • 财政年份:
    2012
  • 资助金额:
    $ 53.22万
  • 项目类别:
Mechanisms of Herceptin resistance
赫赛汀耐药机制
  • 批准号:
    8841327
  • 财政年份:
    2012
  • 资助金额:
    $ 53.22万
  • 项目类别:
Mechanisms of Herceptin resistance
赫赛汀耐药机制
  • 批准号:
    9034335
  • 财政年份:
    2012
  • 资助金额:
    $ 53.22万
  • 项目类别:
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles
使用治疗诊断纳米颗粒靶向治疗三阴性乳腺癌
  • 批准号:
    8333962
  • 财政年份:
    2011
  • 资助金额:
    $ 53.22万
  • 项目类别:
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles
使用治疗诊断纳米颗粒靶向治疗三阴性乳腺癌
  • 批准号:
    8518266
  • 财政年份:
    2011
  • 资助金额:
    $ 53.22万
  • 项目类别:
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles
使用治疗诊断纳米颗粒靶向治疗三阴性乳腺癌
  • 批准号:
    8874343
  • 财政年份:
    2011
  • 资助金额:
    $ 53.22万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 53.22万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 53.22万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.22万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.22万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 53.22万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.22万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 53.22万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 53.22万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 53.22万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.22万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了